The league table of top-selling drugs by global revenues saw a considerable shake-up in 2023, as COVID-19 vaccine and therapeutic sales plummeted, GLP-1 inhibitors took the market by storm, and one-time best-seller Humira lost US patent protection.
One of the most notable features of the top 20 list in 2023 was the huge fall in aggregate revenues
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?